Diabetic Neuropathy - Drug Pipeline Landscape, 2023
Description
Diabetic Neuropathy - Drug Pipeline Landscape, 2023
Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels can damage the nerves over time. This type of damage is called neuropathy. Diabetic neuropathy can affect different parts of the body, including the feet, legs, hands, and arms. It can also affect the digestive system, urinary system, blood vessels, and heart. Diabetic neuropathy is a serious complication of diabetes. It can lead to problems with the feet, legs, and hands. It can also lead to problems with the digestive system, urinary system, blood vessels, and heart.
Diabetic neuropathy can cause due to the high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage nerves. High blood glucose levels can also damage the small blood vessels that nourish nerves with oxygen and nutrients.
Symptoms of diabetic neuropathy includes loss of sensation in their feet, burning or shooting pain in their lower legs, muscle weakness or wasting, bladder problems such as incomplete bladder emptying, vision trouble such as double vision.
Doctors most often diagnose diabetic neuropathy by asking about symptoms and physical examination. The tests include filament test, sensory test, nerve conduction test, autonomic test, and electromyography.
The most common investigative treatments include anti-seizure drugs, antidepressants to ease pain. Symptoms can be eased through lifestyle changes and home remedies like physically active, follow diabetes meal plan, quit smoking, and limit alcoholic drinks to no more than one drink per day.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Neuropathy treatment such as AT-001, VM202, ACY-1215 and others. Key players involved in the development of therapies to treat Diabetic Neuropathy are Applied Therapeutics Inc, AstraZeneca, Celon Pharma SA, Helixmith Co Ltd, Regenacy Pharmaceuticals LLC and others. Two drugs are under late-stage Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I and preclinical stages of development.
Report Highlights
Global Insight Service's, Diabetic Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Neuropathy pipeline drugs. This report covers detailed insights on Diabetic Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels can damage the nerves over time. This type of damage is called neuropathy. Diabetic neuropathy can affect different parts of the body, including the feet, legs, hands, and arms. It can also affect the digestive system, urinary system, blood vessels, and heart. Diabetic neuropathy is a serious complication of diabetes. It can lead to problems with the feet, legs, and hands. It can also lead to problems with the digestive system, urinary system, blood vessels, and heart.
Diabetic neuropathy can cause due to the high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage nerves. High blood glucose levels can also damage the small blood vessels that nourish nerves with oxygen and nutrients.
Symptoms of diabetic neuropathy includes loss of sensation in their feet, burning or shooting pain in their lower legs, muscle weakness or wasting, bladder problems such as incomplete bladder emptying, vision trouble such as double vision.
Doctors most often diagnose diabetic neuropathy by asking about symptoms and physical examination. The tests include filament test, sensory test, nerve conduction test, autonomic test, and electromyography.
The most common investigative treatments include anti-seizure drugs, antidepressants to ease pain. Symptoms can be eased through lifestyle changes and home remedies like physically active, follow diabetes meal plan, quit smoking, and limit alcoholic drinks to no more than one drink per day.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Neuropathy treatment such as AT-001, VM202, ACY-1215 and others. Key players involved in the development of therapies to treat Diabetic Neuropathy are Applied Therapeutics Inc, AstraZeneca, Celon Pharma SA, Helixmith Co Ltd, Regenacy Pharmaceuticals LLC and others. Two drugs are under late-stage Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I and preclinical stages of development.
Report Highlights
Global Insight Service's, Diabetic Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Neuropathy pipeline drugs. This report covers detailed insights on Diabetic Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
99 Pages
- 1. Introduction
- 1.1 Diabetic Neuropathy - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Diabetic Neuropathy
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Diabetic Neuropathy - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase III
- 5.1.1 AT-001
- 5.1.2 VM202
- 5.2 Clinical Stage Drugs - Phase II
- 5.2.1 ACY-1215
- 5.2.2 CNTX-6016
- 5.2.3 GRC 17356
- 5.2.4 MEDI7352
- 5.2.5 MT-8554
- 5.2.6 NYX-2925
- 5.2.7 PG-DN-20WS
- 5.2.8 Trazodone/gabapentin
- 5.2.9 WST-057
- 5.3 Clinical Stage Drugs - Phase I
- 5.3.1 CPL-280
- 5.3.2 RTA 901
- 5.3.3 SYHA1402
- 5.4 Early Stage Drugs - Preclinical
- 5.4.1 EPGN2154
- 5.4.2 GB102
- 5.4.3 GB107
- 5.4.4 MDR-16523
- 5.4.5 MDR-652
- 5.4.6 PTG-630
- 5.4.7 Resiniferatoxin
- 5.4.8 SON-080
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Applied Therapeutics Inc
- 9.2 Aptinyx
- 9.3 AstraZeneca
- 9.4 Aziende Chimiche Riunite Angelini Francesco S.p.A
- 9.5 Celon Pharma SA
- 9.6 Centrexion Therapeutics
- 9.7 CSPC ZhongQi Pharmaceutical Technology Co Ltd
- 9.8 Epigen Biosciences Inc
- 9.9 G&P Bioscience Co Ltd
- 9.10 Glenmark Pharmaceuticals Ltd
- 9.11 Helixmith Co Ltd
- 9.12 Ion Channel Pharmacology LLC
- 9.13 Medifron DBT Co Ltd
- 9.14 Mitsubishi Tanabe Pharma Corporation
- 9.15 Praetego Inc
- 9.16 Pure Green
- 9.17 Reata Pharmaceuticals Inc
- 9.18 Regenacy Pharmaceuticals LLC
- 9.19 Sonnet BioTherapeutics Holdings Inc
- 9.20 WinSanTor Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 11. Appendix
- List of Tables
- Table 1.2 Number of Products under Development by Diabetic Neuropath
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - AT-001/Applied Therapeutics Inc
- Table 2.2 Clinical Trial Details - VM202/Helixmith Co Ltd
- Table 2.3 Clinical Trial Details - ACY-1215/Regenacy Pharmaceuticals LLC
- Table 2.4 Clinical Trial Details - CNTX-6016/Centrexion Therapeutics
- Table 2.5 Clinical Trial Details - GRC 17356/Glenmark Pharmaceuticals Ltd
- Table 2.6 Clinical Trial Details - MEDI7352/AstraZeneca
- Table 2.7 Clinical Trial Details - MT-8554/Mitsubishi Tanabe Pharma Corporation
- Table 2.8 Clinical Trial Details - NYX-2925/Aptinyx
- Table 2.9 Clinical Trial Details - PG-DN-20WS/Pure Green
- Table 2.10 Clinical Trial Details - Trazodone/gabapentin /Aziende Chimiche Riunite Angelini Francesco S.p.A
- Table 2.11 Clinical Trial Details - WST-057/WinSanTor Inc
- Table 2.12 Clinical Trial Details - RTA 901/Reata Pharmaceuticals Inc
- Table 2.13 Clinical Trial Details - SYHA1402 /CSPC ZhongQi Pharmaceutical Technology Co Ltd
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Diabetic Neuropathy, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Diabetic Neuropathy, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Diabetic Neuropathy, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Diabetic Neuropathy, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Diabetic Neuropathy, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
